The overall goal of this SPORE application is to develop more effective targeted molecular therapies and biomarkers for glioblastoma. The four proposed projects of the SPORE focus on 1) targeted therapeutics to treat BRAF-mutant pediatric gliomas; 2) development of improved targeted therapies for IDH-mutant gliomas; 3) combining targeted CDK4/6 inhibitors with immunotherapies to treat glioblastoma; and 4) evaluation of Nlgn3 as a novel therapeutic target in gliomas. The Pathology Core will support the goals of these SPORE Projects by providing expert neuropathologic review, specimen banking, genomic analysis and clinical trial support. In addition, the Pathology Core will be a centralized resource for validated patient derived cell lines and xenografts of gliomas. The Core will also offer innovative CyTOF on a slide multiplex imaging (MIBI), mass spectrometry imaging of drug distribution within tissue sections, and liquid biopsy of circulating tumor cells (CTC) to determine responses to targeted therapies in clinical trials. By centralizing these activities, the Pathology Core will ensure the reproducibility of data and effective use of finite glioma tissue resources essential to the collaborative translational research of the SPORE program.
The goal of the Pathology Core is to provide expert services and support to the Projects of the SPORE. The Core will collect tissue samples and clinical data from patients with gliomas and distribute these to the investigators in the program. The Core will create cell lines and mouse tumor models from tumors for use in the research of the Projects. The Core will perform sequencing of gliomas as well as perform innovative services to look at drug distribution and circulating tumor cells in the blood of patients to see if they respond to targeted therapies.
Showing the most recent 10 out of 84 publications
